Biotech Report: Ultra Man

Innovation is still valued in the orphan-drug space, but the reimbursement bar is rising. NPS Pharma's Eric Pauwels, who's launched five ultra-rare disease products, explains ...

Marketing Research: A Question of Value

When assessing the value of breakthrough drugs, Health Economics & Outcomes Research can help generate the economic profile of a new therapy. Mohan Bala and ...

Leadership Exchange: Thinking More Like a Patient

A major information explosion is just the tip of the iceberg in the paradigm shift that is taking place between pharma, marketers and the patients ...

Therapeutic Focus 2014: Oncology

Immunotherapy is an emerging powerhouse in cancer treatment. Early gains being made in multiple tumor types provide a glimpse of the effectiveness of several agents ...

Headliner: Galderma CEO confronts challenges

Stuart Raetzman, CEO, Galderma Labs

Multichannel Marketing: At Your Service

Pharma is moving toward a broader treatment paradigm based on providing additional services for patients. Boris Kushkuley describes what the Pill+ model looks like, and ...

Latest News

Sanofi expands Gaucher disease portfolio

Sanofi expands Gaucher disease portfolio

The oral medication Cerdelga joins Cerezyme in its Fabry disease arsenal. Sanofi expects the drug will be priced "on par" with Cerezyme, which goes for around $300,000 a year in the US.

Amicus seeks to upset Fabry market

Amicus seeks to upset Fabry market

Phase-III tests indicate patients may be able to switch from injectable enzyme-replacement therapies, like Fabrazyme, to the firm's oral drug.

Five things for pharma marketers to know: Wednesday, August 20

Five things for pharma marketers to know: Wednesday, August 20

Novartis explores the virtual care space, a court has dismissed a lawsuit against IPAB, Doctors Without Borders calls the Ebola outbreak "a complete disaster" and Pfizer becomes the first pharma company to pair with the Crohn's and Colitis Foundation of America.

FDA kind of OKs Lilly/BI's Lantus look-alike

FDA kind of OKs Lilly/BI's Lantus look-alike

Sanofi's patent lawsuit triggered the tentative approval of the Lilly-BI Lantus competitor.

GSK relaunches COPD.com

GSK relaunches COPD.com

The refresh launched soon after the company encouraged investors to take a long view of GSK as the firm posted weak respiratory numbers.

Web Exclusive

How Can Pharmaceutical Companies Build Closer Relationships With Social Patients?

How Can Pharmaceutical Companies Build Closer Relationships With Social Patients?

This year, FDA has finally begun to offer some guidance to marketers about digital media. Here's what social patients say they want

As Pharma Slowly Opens Up, Patients Are Engaging Themselves

As Pharma Slowly Opens Up, Patients Are Engaging Themselves

Influential patients are reaching critical mass. What can't they do?

In Brief

DOJ closes Brilinta investigation

AstraZeneca announced the end of the investigation Tuesday.

Doctors back unique biosimilar names

A host of doctors has asked FDA Commissioner Margaret Hamburg to back a naming convention that would require biologics and biosimilars to have different names.

Roche has no rights to Sovaldi, panel rules

Despite a collaboration with original Sovaldi owner Pharmasset in 2004, a panel ruled Roche has no rights to HCV treatment Sovaldi.

MM&M Awards Gallery

A Star-Studded Evening

Click on the image above to see a gallery of images from the 2013 MM&M Awards dinner

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

Agency Spotlight


Email Newsletters